Wellgistics Health, Inc. announced on August 14, 2025, the termination of its equity purchase agreement (ELOC) with Hudson Global Ventures, LLC. This ELOC was a facility that could have provided up to $50 million in capital. The company stated the ELOC was an effective tool that nearly doubled its original IPO raise.
The termination impacts the company's capital structure and future financing options. While the ELOC was a source of potential capital, its termination indicates a shift in the company's funding strategy. This decision is made to further support its growth strategy.
Wellgistics Health continues its focus on next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment. The company will pursue other avenues to manage its liquidity and capital needs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.